AR119334A1 - TRANSLATION INHIBITORS AND THEIR USES - Google Patents

TRANSLATION INHIBITORS AND THEIR USES

Info

Publication number
AR119334A1
AR119334A1 ARP200101871A ARP200101871A AR119334A1 AR 119334 A1 AR119334 A1 AR 119334A1 AR P200101871 A ARP200101871 A AR P200101871A AR P200101871 A ARP200101871 A AR P200101871A AR 119334 A1 AR119334 A1 AR 119334A1
Authority
AR
Argentina
Prior art keywords
inhibitors
translation
translation inhibitors
eif4a
mnk
Prior art date
Application number
ARP200101871A
Other languages
Spanish (es)
Inventor
Kevin R Webster
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of AR119334A1 publication Critical patent/AR119334A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Composiciones que comprenden una pluralidad de inhibidores que actúan sobre factores de la traducción implicados en la iniciación de la traducción de mARN dependiente de cap, que incluyen inhibidores contra eIF4A, eIF4E, MNK, o cualquier combinación de estos. También métodos para el tratamiento de trastornos hiperproliferativos, tales como cáncer, con tratamientos conjuntos de inhibidores de la traducción.Compositions comprising a plurality of inhibitors that act on translation factors involved in cap-dependent mRNA translation initiation, including inhibitors against eIF4A, eIF4E, MNK, or any combination of these. Also methods for the treatment of hyperproliferative disorders, such as cancer, with co-treatments of translation inhibitors.

ARP200101871A 2019-07-02 2020-07-01 TRANSLATION INHIBITORS AND THEIR USES AR119334A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962869897P 2019-07-02 2019-07-02

Publications (1)

Publication Number Publication Date
AR119334A1 true AR119334A1 (en) 2021-12-09

Family

ID=71452520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101871A AR119334A1 (en) 2019-07-02 2020-07-01 TRANSLATION INHIBITORS AND THEIR USES

Country Status (4)

Country Link
JP (1) JP2021008453A (en)
AR (1) AR119334A1 (en)
TW (1) TW202114681A (en)
WO (1) WO2021001743A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114404400A (en) * 2022-01-24 2022-04-29 深圳承启生物科技有限公司 Translation inhibitor without occupying ribosome resource as antitumor drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
CN1046944C (en) 1993-12-17 1999-12-01 山道士有限公司 Rapamycin derivatives useful as immunosuppressants
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
GB9914480D0 (en) 1999-06-21 1999-08-18 Univ Dundee Use of peptides
ATE554764T1 (en) 2002-03-13 2012-05-15 Texas A & M Univ Sys EFFECTIVE SIMPLIFIED DERIVATIVES OF IMMUNOSUPPRESSANTS
US7737134B2 (en) 2002-03-13 2010-06-15 The Texas A & M University System Anticancer agents and use
EP1668130A2 (en) 2003-09-18 2006-06-14 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
JP5225691B2 (en) 2005-01-21 2013-07-03 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Regulation of protein synthesis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AR077280A1 (en) 2009-06-29 2011-08-17 Incyte Corp PYRIMIDINONES AS PI3K INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011136744A1 (en) 2010-04-27 2011-11-03 Agency For Science, Technology And Research Eif4e binding peptides
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2013016658A1 (en) 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
SI2751109T1 (en) 2011-09-02 2017-03-31 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
ES2689921T3 (en) * 2012-11-30 2018-11-16 Novomedix, Llc Substituted biarylsulfonamides and their uses
SG11201507798YA (en) 2013-03-21 2015-10-29 Agency Science Tech & Res STAPLING eIF4E INTERACTING PEPTIDES
TWI713455B (en) 2014-06-25 2020-12-21 美商伊凡克特治療公司 Mnk inhibitors and methods related thereto
CA2981472C (en) 2015-03-31 2023-08-22 The Texas A&M University System Alpha-amino pateamine a derivatives and methods for treating chronic lymphocytic leukemia
US10702526B2 (en) 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018218072A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response

Also Published As

Publication number Publication date
WO2021001743A1 (en) 2021-01-07
TW202114681A (en) 2021-04-16
JP2021008453A (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2019000820A1 (en) Compounds, compositions and their uses to inhibit arginase activity. (divisional application 201801134)
CO2019007839A2 (en) Compositions and methods for inhibiting the action of arginase
CL2017001956A1 (en) Tau antisense oligomers and their use
CO2020001220A2 (en) Compounds, compositions and methods
CL2018001404A1 (en) Bivalent bromodomain inhibitors and uses thereof.
SV2017005461A (en) BENZAMIDS REPLACED WITH 1,3-TIAZOL-2-ILO
BR112018073328A2 (en) combination, pharmaceutical composition, kit, cancer treatment method, cell level reduction method, cell level reduction method, activity increasing method, cytotoxicity increasing method
CL2017001893A1 (en) Use of prg4 as an anti-inflammatory agent
CL2017001046A1 (en) Bromodomain Inhibitors
MX2021014815A (en) Methods of treating inflammation or neuropathic pain.
CO2018000224A2 (en) Notch pathway signaling inhibitor compounds
CL2019002251A1 (en) Antibodies against tryptase, compositions of these and uses of these.
BR112018009311A2 (en) A method for treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplantation.
CR20160047A (en) RORC2 INHIBITORS AND THEIR METHODS OF USE
MX2020004179A (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use.
ECSP19084085A (en) MAGL PYRAZOLIC INHIBITORS
ECSP19057403A (en) THERAPEUTIC USES OF AN INSECT POWDER
CL2020002624A1 (en) Stable anti-cd79b immunoconjugate formulations.
CO2016000671A1 (en) Constructions of variants of sirp-alfa and their uses
BR112017024908A2 (en) therapeutic uses of 4-chloroquinurenine
BR112021017774A2 (en) Low Dose Cytokine Co-Administered With IRGD to Treat Cancer
AR119334A1 (en) TRANSLATION INHIBITORS AND THEIR USES
CO2017001076A2 (en) Antihyperalgesic, anti-allodinic and anti-inflammatory pharmaceutical compositions containing pregabalin and meloxicam
NI201900128A (en) COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD CARE TREATMENT FOR HEMATOLOGICAL CANCER, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
CL2021003442A1 (en) Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer.